Reproductive Medicine Daily Report: 01/23/2024

A phase I/II study evaluated the pharmacokinetics, pharmacodynamics, and safety of drospirenone in 12 Japanese women as an oral contraceptive (1). The pharmacokinetics in Japanese women were similar to those in previous studies in Caucasians. Repeated administration maintained low plasma progesterone levels, indicating effective inhibition of ovulation. Adverse events were observed in 11 (91.7%) subjects, with genital hemorrhage being the most common (50.0%).

Reference

Kitamura K, Colli E, Azuma R, Kikuyama R, Kanai M. A phase I/II study evaluating the pharmacokinetics, pharmacodynamics, and safety of drospirenone as an oral contraceptive in Japanese women. J Obstet Gynaecol Res. 2024 Jan 23. doi: 10.1111/jog.15881. Epub ahead of print. PMID: 38262424.